Education
About Us
Working with TipRanks
Follow Us
Xbrane Biopharma AB (SE:XBRANE)
:XBRANE
RESEARCH TOOLSreports
XBRANE Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr0.13 - kr0.36
Previous CloseN/A
Volume1.93M
Average Volume (3M)13.61M
Market Cap
kr383.05M
Enterprise ValueN/A
Total Cash (Recent Filing)kr124.33M
Total Debt (Recent Filing)kr191.72M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 27, 2025EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,532,190,300
10 Day Avg. Volume28,838,022
30 Day Avg. Volume13,606,754
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.12
Price to Sales (P/S)0.00
P/FCF Ratio-1.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Xbrane Biopharma AB News
---
XBRANE FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was kr0.13 and its highest was kr0.36 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is kr383.05M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is Aug 27, 2025 which is in 102 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on May 08, 2025. The company reported kr0.007 earnings per share for the quarter, beating the consensus estimate of -kr0.028 by kr0.035.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate is 0.16.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 1,532,190,300 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of kr0.007 in its last earnings report, beating expectations of -kr0.028. Following the earnings report the stock price went up 9.626%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in SE:XBRANE
---
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
---
Technical Analysis
Oncopeptides AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Isofol Medical AB
―
Intervacc AB
―
---